Arbutus Biopharma Corp
NASDAQ: ABUS
$3.75
Closing Price on November 8, 2024
ABUS Stock Chart and Intraday Price
ABUS Stock Data
Asset Type | Stock |
Exchange | NASDAQ |
Currency | USD |
Country | USA |
Sector | LIFE SCIENCES |
Industry | PHARMACEUTICAL PREPARATIONS |
Address | 100-8900 GLENLYON PARKWAY, BURNABY, BC, CA |
Fiscal Year End | December |
Latest Quarter | 9/30/2023 |
Market Cap | 474.02M USD |
Shares Outstanding | 169,900,000 |
ABUS Articles
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Published:
Arbutus Biopharma shares jumped on Tuesday after the company reported positive data from its early-stage clinical trial in patients with chronic hepatitis B virus infection.
Published: